High Prevalence of Cancer and R&D in Fibrosarcoma to Augment Growth of Fibrosarcoma Drugs Market

A fibrosarcoma is an inflamed (malignant) tumor that originates from the connective fibrous tissue located at the ends of the bones of the lower arm or leg and then proceeds to spread to other surrounding tissues, causing extreme pain and complications. It's a form of cancer that typically grows slowly over an extended period of time. Fibrosarcoma may develop for several reasons, including: primary tumors at the facial prominences on one or both sides of the heart; fibrosarcoma may develop in response to an infection (such as those that occur in the stomach or esophagus); tumors may also develop on other areas of the body other than the skin. If you have any of these symptoms, you should contact your physician immediately. However, since the symptoms of fibrosarcoma are similar to those of other diseases, and because it's difficult to determine whether a disease exists, most people with fibrosarcoma are sent for check-ups each year.

Market Dynamics

High prevalence of cancer is expected to propel growth of the fibrosarcoma drugs market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Moreover, increasing funding in cancer R&D is also expected to aid in growth of the fibrosarcoma drugs market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19.

R&D in fibrosarcoma is expected to offer lucrative growth opportunities for players in the fibrosarcoma drugs market. For instance, in January 2021, researchers from Children's Hospital of Philadelphia reported that neurotrophic tyrosine receptor kinase (NTRK) fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.

Competitive Analysis

Major players operating in fibrosarcoma drugs market include, Cadila Healthcare Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Baxter International Inc., Eli Lilly and Company, Cullgen Inc., Pfizer limited, Johnson & Johnson., and Celon Laboratories Pvt. Ltd.

Major players operating in fibrosarcoma drugs market are focused on R&D to expand their product portfolio. For instance, in October 2020, Cullgen Inc. announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Comments

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....

North America is expected to lead the global cosmetology market due to growing number of minimally invasive surgeries in the region

Market Overview: Cosmetology is the field of a beauty practice that includes a variety of practices aimed at making individual’s look and feel their best. Competitive Landscape: GC Aesthetics, Mentor Worldwide LLC, Sientra Inc., Zimmer Holdings Inc., 3M Health Care, Allergan, Inc., Implantech Associates Inc., Institut Straumann AG, Nobel Biocare Holding AG, and Spectrum Designs Medical. Key Market Drivers: An increasing number of cosmetic surgeries is expected to expand the global cosmetology market size. For instance, according to American Society of Plastic Surgeons (ASPS) 2017 reports, around 17.5 million cosmetic surgeries were performed in 2017, U.S. among which breast augmentation, liposuction, and nose reshaping were the top three procedures. High preferences for Botox surgeries which are used to reduce wrinkles and maintain youthful skin is again fostering the growth of the market growth. According to the same source, around 65% of women prefer Botul...

Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market is Expected to Grow Drastically, Assured By Experts From 2023 To 2028

Surgical hemostat is a surgical tool used in many surgical procedures to control bleeding. Surgical hemostats covered in this report include thrombin-based, combination hemostats, oxidized regenerated cellulose-based, gelatin-based, and collagen-based. Internal tissue sealants are typically used in surgeries to bind or hold internal tissues such as blood vessels, internal organs, bone cartilage, dura matter and others. The global surgical hemostats, internal tissue sealants and adhesion barriers market is estimated to account for US$ 4,231.4 Mn in terms of value in 2020 and is expected to reach US$ 7,346.7 Mn by the end of 2027 Global Surgical Hemostats, Internal Tissue Sealants and Adhesion Barriers Market: Drivers Increasing number of surgical procedures is expected to propel growth of the global surgical hemostats , internal tissue sealants and adhesion barriers market over the forecast period. For instance, according to ‘Surgical operations and procedures sta...

Healthcare News

Search This Blog